CRL stock forecast, quote, news & analysis
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services... Show more
Why Charles River Laboratories (CRL) Stock Is Up +22.7% in the Last 30 Days
Key Takeaways
- Charles River Laboratories (CRL) shares surged approximately 22.7% over the past 30 days, climbing from $188.47 to above $231, fueled by a wave of analyst upgrades and improving biotech funding conditions.
- Morgan Stanley upgraded CRL to Overweight with a $220 price target in mid-June, while CLSA, Argus, and Bernstein all raised their outlooks, citing recovering demand in preclinical research services.
- The company's strategic portfolio restructuring — including the divestiture of its CDMO and Cell Solutions businesses — has sharpened investor focus on its higher-margin core operations.
- Q1 2026 earnings beat consensus estimates, with revenue of $995.8 million and non-GAAP EPS of $2.06, reinforcing confidence in management's turnaround narrative.
- AI-driven initiatives, including an expanded digital pathology platform and a collaboration with Eli Lilly's TuneLab, have added a technology-growth dimension to the investment thesis.
- Over the broader quarter, CRL staged a dramatic recovery from mid-May lows near $150, reflecting a bottoming in biopharma demand and accelerating institutional inflows.
Charles River Laboratories (CRL) Company Overview and Market Position
Charles River Laboratories International, Inc. is a premier global provider of preclinical and clinical support services for the pharmaceutical, biotechnology, and medical device industries. Founded in 1947 and headquartered in Wilmington, Massachusetts, the company operates across three core segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. CRL supplies laboratory animal models, conducts toxicology and safety studies, and provides biologics testing, microbial solutions, and cell and gene therapy manufacturing support. With approximately 40% to 45% of revenue derived from small and mid-sized biotech clients, Charles River is highly leveraged to the health of biopharma funding cycles — a dynamic that makes the stock closely watched by healthcare investors seeking exposure to drug development outsourcing trends.
Charles River Laboratories (CRL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRL shares have advanced approximately 22.7%, rising from a close of $188.47 on June 15, 2026, to an intraday level above $231. The rally accelerated in late June following a cascade of bullish analyst actions and has continued into mid-July with sustained upward momentum. The stock has now climbed more than 50% above its 52-week low of $144.26, reached earlier in 2026.
Looking at the broader quarter, the trajectory has been even more pronounced. CRL entered the period under significant pressure, bottoming near $150 in mid-May as investors digested soft organic revenue trends and the impact of portfolio divestitures. Since that trough, the stock has staged a powerful recovery — rallying over 50% — as improving biotech funding data, analyst upgrades, and tangible progress on restructuring initiatives reshaped market sentiment. The 50-day moving average has crossed above the 200-day moving average, a technical signal often interpreted as a bullish long-term trend reversal.
What Drove CRL Stock Price in the Last 30 Days
The primary catalyst behind CRL's 30-day surge was a concentrated series of analyst upgrades and price-target increases. On June 17, Morgan Stanley upgraded the stock to Overweight from Equal-weight, lifting its price target to $220 from $185 and explicitly citing rebounding biopharma funding as a tailwind for Charles River's preclinical services business. This followed a May 29 upgrade from CLSA, which moved CRL from Hold to Outperform with a $219 target, pointing to a more favorable regulatory environment in both the U.S. and China.
In early July, Argus raised its price target to $250 with a Buy rating, while Sanford C. Bernstein initiated coverage with a $250 target. Mizuho followed on July 13, raising its target to $230 from $192. The cumulative effect of these revisions — coming from firms with significant institutional followings — drove substantial buying interest and short-covering activity.
Beyond analyst sentiment, Charles River's Q1 2026 results, reported on May 7, beat expectations on both revenue ($995.8 million versus the $977.5 million consensus) and non-GAAP earnings per share ($2.06 versus $1.96). The company also reaffirmed its full-year 2026 non-GAAP EPS guidance of $10.80 to $11.30 and outlined $100 million in incremental cost savings. Additionally, the completed divestiture of the CDMO and Cell Solutions businesses to GI Partners and the agreed sale of European Discovery Services assets to IQVIA streamlined the corporate structure and refocused the portfolio on higher-return segments.
Technology-driven announcements also contributed to positive sentiment, including the expansion of Charles River's AI-enabled digital pathology platform, a collaboration with Eli Lilly's TuneLab for AI/ML drug discovery, and a partnership with Arovella Therapeutics for GMP-grade NGS cell characterization services.
What Drove CRL Stock Performance Over the Last Quarter
The quarterly performance of CRL reflects a broader narrative of stabilization and recovery in the contract research organization (CRO) space. After spending much of early 2026 under pressure — driven by cautious biopharma client spending, declining organic revenue, and uncertainty around restructuring — the stock found a floor in mid-May. The turning point coincided with the closing of key divestitures, a leadership transition that saw COO Birgit Girshick succeed longtime CEO James Foster, and mounting evidence that biotech funding was accelerating after a prolonged drought.
Institutional positioning also played a role. Despite some high-profile insider selling — including Director James Foster's sale of 75,000 shares at $225 in late June under a prearranged Rule 10b5-1 plan — aggregate institutional ownership remained near 99%, and several major asset managers meaningfully increased their positions during the first half of 2026. The combination of bottoming fundamentals, portfolio clarity, and strengthening demand indicators created a powerful setup for the quarter's rally.
Trending AI Robots
For investors seeking data-driven approaches to navigate fast-moving stocks like Charles River Laboratories, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading robots that actively trade thousands of tickers across diverse strategies and timeframes, but only the most relevant and consistently high-performing bots are featured in this section. Each robot employs distinct technical, fundamental, or pattern-recognition methodologies, enabling traders to evaluate approaches that align with their risk tolerance and market outlook. Browsing the Trending AI Robots page can provide a valuable lens into how algorithmic strategies are positioning in names like CRL and the broader healthcare services sector.
CRL Stock Forecast Drivers: What Investors Should Watch Next
The next major catalyst for CRL will be its second-quarter 2026 earnings report, scheduled for release on August 5, 2026, before the market opens. Investors will scrutinize organic revenue trends in the DSA segment, the pace of bookings conversion from improved biotech funding, and updated guidance on margin expansion. Management has projected 120 to 150 basis points of operating margin improvement for 2026, with most of the gains back-half weighted — making Q2 results a critical checkpoint.
Macroeconomic factors, including the trajectory of interest rates and their impact on biotech venture capital flows, remain important external variables. Competitive dynamics, particularly the growing adoption of AI-enabled drug discovery tools by large pharmaceutical companies, could influence the demand outlook for outsourced preclinical services. Additionally, the integration of recent divestitures and the execution of the company's $300 million annualized cost-savings program will be closely monitored by the analyst community. While the recent rally reflects genuine fundamental improvement, the stock's valuation has expanded considerably, raising the bar for upcoming execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRL in +1.02% Uptrend, growing for three consecutive days on July 06, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRL advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on CRL as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 50-day moving average for CRL moved above the 200-day moving average on July 06, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 207 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CRL moved out of overbought territory on July 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for CRL turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CRL broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.808) is normal, around the industry mean (69.994). CRL has a moderately high P/E Ratio (577.050) as compared to the industry average of (159.234). CRL's Projected Growth (PEG Ratio) (0.122) is slightly lower than the industry average of (1.659). CRL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (2.837) is also within normal values, averaging (8.241).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of laboratory testing and research services on a contract basis
Industry MedicalSpecialties